Operating Lease, Liability, Noncurrent of Rubius Therapeutics, Inc. from 31 Dec 2018 to 31 Dec 2022
- Taxonomy & unit
- us-gaap: USD
- Description
- Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
- Summary
-
Rubius Therapeutics, Inc. quarterly Operating Lease, Liability, Noncurrent in USD history and change rate from 31 Dec 2018 to 31 Dec 2022.
- Rubius Therapeutics, Inc. Operating Lease, Liability, Noncurrent for the quarter ending 31 Dec 2022 was $0, a 100% decline year-over-year.
- Source SEC data
- View on sec.gov
Operating Lease, Liability, Noncurrent, Quarterly (USD)
Operating Lease, Liability, Noncurrent, YoY Quarterly Change (%)
Rubius Therapeutics, Inc. Quarterly Operating Lease, Liability, Noncurrent (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2022 | $0 | -$28,291,000 | -100% | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2022 | $24,657,000 | -$4,753,000 | -16% | 30 Sep 2022 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $25,882,000 | -$4,668,000 | -15% | 30 Jun 2022 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $27,078,000 | -$4,584,000 | -14% | 31 Mar 2022 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2021 | $28,291,000 | -$4,471,000 | -14% | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2021 | $29,410,000 | -$4,130,000 | -12% | 30 Sep 2021 | 10-Q | 08 Nov 2021 | 2021 | Q3 |
| Q2 2021 | $30,550,000 | -$4,104,000 | -12% | 30 Jun 2021 | 10-Q | 09 Aug 2021 | 2021 | Q2 |
| Q1 2021 | $31,662,000 | -$4,104,000 | -11% | 31 Mar 2021 | 10-Q/A | 20 Aug 2021 | 2021 | Q1 |
| Q4 2020 | $32,762,000 | -$4,105,000 | -11% | 31 Dec 2020 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2020 | $33,540,000 | -$7,899,000 | -19% | 30 Sep 2020 | 10-Q | 09 Nov 2020 | 2020 | Q3 |
| Q2 2020 | $34,654,000 | +$11,517,000 | +50% | 30 Jun 2020 | 10-Q | 10 Aug 2020 | 2020 | Q2 |
| Q1 2020 | $35,766,000 | +$11,713,000 | +49% | 31 Mar 2020 | 10-Q | 11 May 2020 | 2020 | Q1 |
| Q4 2019 | $36,867,000 | -$4,574,000 | -11% | 31 Dec 2019 | 10-K | 25 Feb 2022 | 2021 | FY |
| Q3 2019 | $41,439,000 | 30 Sep 2019 | 10-Q | 14 Nov 2019 | 2019 | Q3 | ||
| Q2 2019 | $23,137,000 | 30 Jun 2019 | 10-Q | 13 Aug 2019 | 2019 | Q2 | ||
| Q1 2019 | $24,053,000 | 31 Mar 2019 | 10-Q | 15 May 2019 | 2019 | Q1 | ||
| Q4 2018 | $41,441,000 | 31 Dec 2018 | 10-Q | 14 Nov 2019 | 2019 | Q3 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.